The False Claims Act (FCA), codified at 31 U.S.C. §§ 3729-3733, creates a distinct and often underappreciated exposure for research institutions when a clinical trial’s costs are split between a commercial or federal sponsor and Medicare or Medicaid. This is a different fact pattern from FCA liability tied to a grant application, progress report, or effort certification submitted directly to a federal funder — see the companion guide on the False Claims Act in research grant compliance for that side of FCA exposure. Here, the “claim” at issue is a routine Medicare or Medicaid billing claim submitted through the institution’s hospital or clinic billing system for patient care delivered to a trial participant, and the core question is not whether a certification to a funder was accurate, but whether the government insurance program was billed for something the trial sponsor had already agreed — contractually, in the clinical trial agreement — to pay for. This guide covers how that exposure arises, the Medicare coverage framework that determines who is supposed to pay for what, real enforcement history, the qui tam mechanics specific to this context, and how it intersects with the Stark Law and the Anti-Kickback Statute.
How clinical trial billing creates a distinct kind of FCA exposure
A clinical trial that enrolls Medicare or Medicaid beneficiaries typically has three potential payers for any given item or procedure a participant receives: the trial sponsor (who pays, per the clinical trial agreement budget, for procedures performed specifically because the protocol requires them), Medicare or Medicaid (who may pay for “routine costs” of patient care that would have occurred regardless of the trial), and the patient (who may owe standard copayment or coinsurance on whatever Medicare does cover). The FCA risk in this setting is structural: because the same office of visit, scan, or lab draw can plausibly be billed to more than one of these payers, an institution’s research billing and hospital billing systems have to agree, before a single claim is submitted, on exactly one payer for each line item. When that reconciliation fails — because a study coordinator doesn’t flag a charge as research-related, because a coverage analysis was never completed or wasn’t followed by the billing office, or because a system simply defaults every charge to the patient’s insurance — the result is a claim submitted to Medicare for a service the sponsor was already paying for, which is the fact pattern behind essentially every research-sector clinical-trial-billing FCA settlement described below.
The Medicare Clinical Trial Policy (NCD 310.1) and coverage analysis
Medicare’s coverage of clinical trial participation is governed by National Coverage Determination (NCD) 310.1, “Routine Costs in Clinical Trials”, effective July 9, 2007. Under NCD 310.1, Medicare covers the routine costs of a qualifying clinical trial — items and services that would normally be furnished to the patient as part of standard care whether or not the trial existed, plus items and services otherwise covered by Medicare (i.e., they fall within a Medicare benefit category, aren’t statutorily excluded, and aren’t subject to a national non-coverage decision) that happen to be provided in either arm of the trial. Routine costs specifically exclude the investigational item or service itself, unless that item or service would be covered outside the trial. Separately, Medicare will cover the reasonable and necessary treatment of complications arising from participation in any clinical trial, qualifying or not.
A trial “qualifies” for this routine-costs coverage if its subject or purpose evaluates an item or service within a Medicare benefit category, it has genuine therapeutic intent (rather than testing toxicity or disease pathophysiology exclusively in healthy subjects), and — for trials of a therapeutic intervention — it enrolls patients with the diagnosed condition rather than healthy volunteers. A trial is automatically deemed to satisfy these criteria if it is funded by NIH, CDC, AHRQ, CMS, the Department of Defense, or the VA, or if it is conducted under an FDA Investigational New Drug (IND) application (or is an IND-exempt drug trial under 21 CFR 312.2(b)(1)).
Before a trial opens to enrollment, a research billing compliance function — typically the institution’s clinical trials office working with hospital/professional billing compliance staff — performs a coverage analysis: a line-by-line mapping of every protocol-required visit, procedure, and test against the qualifying-trial criteria and the sponsor’s budget, assigning each item to exactly one of the three payers described above. The coverage analysis, not the protocol or the consent form, is what the billing system is actually supposed to follow when a claim is generated — which is why an out-of-date, incomplete, or never-implemented coverage analysis is one of the most common root causes behind the double-billing fact pattern discussed next.
The core fact pattern: double-billing Medicare and the trial sponsor for the same service
Providers are not permitted to bill Medicare for medical care and services that the clinical trial sponsor has agreed, under the clinical trial agreement, to pay for. When an institution bills Medicare for an item the sponsor is already covering — and, in the worst cases, actually is separately paid by the sponsor for that same item — the institution has been paid twice for one service, and the Medicare claim is false because it represents to the government that Medicare, rather than the sponsor, was responsible for payment. Two real, publicly announced Department of Justice settlements illustrate the pattern:
- University of Alabama at Birmingham (2005) — UAB and two affiliated entities paid $3.39 million to resolve a qui tam action alleging both that researchers’ grant-funded effort was overstated on federal applications and that the university unlawfully billed Medicare for clinical trial items and services that were also billed to the trial sponsor. The two whistleblowers — a physician formerly employed by the university’s faculty practice plan and a research compliance officer — shared $395,000 of the recovery.
- Emory University (2013) — Emory paid $1.5 million to resolve allegations, arising from oncology clinical trials conducted at its Winship Cancer Institute between 2001 and 2010, that it billed Medicare and Medicaid for services the trial sponsor had agreed to pay for — and, in some instances, had already paid for — resulting in the university being paid twice for the same service. The case was brought by a former Emory employee under the FCA’s qui tam provisions.
Neither case turned on any dispute about the science or the informed-consent process; both turned entirely on whether the correct payer had been billed for a given line item — precisely the determination a coverage analysis exists to make and a billing system has to enforce claim by claim.
Qui tam mechanics in a clinical-trial-billing case
The underlying qui tam mechanism is the same one that drives FCA cases generally — a private relator files suit under seal under 31 U.S.C. § 3730(b), the government investigates and decides whether to intervene, and a successful relator recovers between 15% and 30% of any recovery under § 3730(d), depending on whether the government intervened. See the companion guide on FCA in research grant compliance for the full mechanics of that provision. What differs in a clinical-trial-billing case is who the relator typically is. Grant-fraud relators tend to be lab staff, grants administrators, or research-compliance officers with visibility into effort records and progress reports. Clinical-trial-billing relators are more often research billing coordinators, hospital revenue-cycle or coding staff, or clinical research coordinators who reconcile charges against the coverage analysis and the clinical trial agreement budget in the ordinary course of their work — exactly the role that noticed the fact pattern in the UAB case above. That makes an institution’s own research billing compliance function, not only its scientific or grants-compliance offices, a meaningful point of FCA risk and FCA risk mitigation simultaneously.
Stark Law and the Anti-Kickback Statute: where trial payments to investigators intersect FCA risk
Clinical trial billing compliance does not stop at the coverage analysis. Payments an institution or sponsor makes to a principal investigator or a trial site — per-subject enrollment payments, recruitment support, or investigator compensation — sit inside two additional federal healthcare fraud statutes that can independently generate FCA liability:
- The Physician Self-Referral Law (“Stark Law”), 42 U.S.C. § 1395nn, generally prohibits a physician from referring Medicare patients for designated health services to an entity with which the physician has a financial relationship, unless an exception applies. Investigator payment arrangements that aren’t set at fair market value in advance, and that aren’t reasonably tied to the actual research services performed, can create exactly this kind of financial relationship.
- The Anti-Kickback Statute (AKS), 42 U.S.C. § 1320a-7b(b), is a criminal statute that prohibits knowingly offering, paying, soliciting, or receiving remuneration to induce referrals of, or generate business involving, items or services reimbursable by a federal health care program. A per-subject or recruitment payment that functions as an inducement to enroll or refer patients — rather than fair compensation for research work actually performed — can implicate the AKS even where the trial’s science and consent process are entirely sound.
The link to FCA liability is direct: claims submitted to Medicare or Medicaid that result from an AKS violation are automatically treated as false claims for FCA purposes, and a Stark-law-tainted claim is independently non-payable under the Stark statute’s own billing prohibition. In practice, this means research billing compliance and institutional conflict-of-interest / investigator-payment review are not separate silos from an FCA standpoint — a per-subject payment structure that a research contracts office signs off on without fair-market-value review can generate FCA exposure just as directly as a miscoded claim can.
How this differs from general grant-related FCA exposure
The grant-compliance side of FCA exposure centers on claims made directly to a federal funder — a grant application, a progress report, an effort certification, a current-and-pending-support disclosure. The government is the direct counterparty on those claims. Clinical-trial-billing FCA exposure instead runs through a completely different claims channel: routine Medicare or Medicaid claims submitted through the institution’s clinical or hospital billing system for patient care, where the government is acting as a health insurer rather than as a research funder. The two can and do coexist on the same federally funded trial — the UAB settlement above combined an effort-overstatement allegation with a double-billing allegation in a single case — but they are governed by different coverage rules (2 CFR 200 cost principles for the grant side; NCD 310.1 and the Medicare Benefit Policy Manual for the billing side), reviewed by different institutional offices in most institutions (sponsored programs versus clinical trials/hospital billing compliance), and require separate controls to manage.
Operational controls that reduce clinical-trial-billing FCA exposure
- A completed, current coverage analysis before enrollment opens, built directly against NCD 310.1’s qualifying-trial criteria and the executed clinical trial agreement budget — and re-run whenever the protocol or the budget is amended, since a coverage analysis tied to an outdated budget is a recurring source of billing errors.
- A billing designation that travels with the order, so that when a protocol-required visit or procedure is scheduled in the hospital’s clinical system, the charge is flagged at the point of order entry as sponsor-billable, Medicare-billable, or patient-billable — rather than relying on manual reconciliation after the claim has already been submitted.
- Reconciliation between the clinical trials office and hospital billing on a recurring (not only annual) basis, comparing what was actually billed to Medicare against the coverage analysis and the sponsor invoicing record for the same participant and visit.
- Fair-market-value review of investigator and site payments before a clinical trial agreement is executed, documented against the actual research services the payment compensates, to manage the Stark/AKS exposure described above.
- A functioning internal reporting channel and prompt corrective action when billing staff raise a concern — because, as in the UAB case, the person who identifies a double-billing pattern in the ordinary course of reconciling charges is often positioned to become a relator if the concern goes unaddressed.
- Use of the HHS Office of Inspector General’s Self-Disclosure Protocol where an institution identifies a billing error with potential FCA exposure on its own, since a timely, voluntary self-disclosure is treated materially differently by DOJ and OIG than a violation surfaced through a qui tam suit or external audit.
None of this substitutes for institutional counsel once an actual billing-compliance concern is identified — but the day-to-day discipline of maintaining an accurate, current coverage analysis and enforcing it at the point of billing is what keeps a research institution out of the fact pattern behind the settlements above.
Frequently asked questions
Does the False Claims Act apply to clinical trial billing separately from grant fraud?
Yes. Billing Medicare or Medicaid for a clinical trial participant’s care is a separate claims channel from a grant application or progress report submitted to a federal funder, and it is governed by a different coverage framework (NCD 310.1) rather than by grant cost principles. An institution can face FCA exposure on the billing side, the grant side, or — as in the UAB settlement — both, arising from the same trial.
What is a coverage analysis and why does it matter for FCA risk?
A coverage analysis is a line-by-line assignment of every protocol-required item and visit to a single payer — the sponsor, Medicare/Medicaid, or the patient — performed against NCD 310.1’s qualifying-trial criteria and the trial’s budget before enrollment opens. It is the document a billing system is supposed to follow when generating a claim; an outdated or unimplemented coverage analysis is a common root cause of the double-billing fact pattern that has produced real FCA settlements.
Can double-billing Medicare and a trial sponsor happen without intent to defraud?
Ordinary negligence alone does not meet the FCA’s “knowing” standard, but the standard also reaches deliberate ignorance and reckless disregard. An institution with no functioning coverage-analysis process, or one that is on notice of a reconciliation gap between research billing and hospital billing and does not correct it, can be found to have acted with reckless disregard even without anyone intending to defraud Medicare.
How do the Stark Law and Anti-Kickback Statute relate to clinical trial billing compliance?
They govern a related but separate risk: payments to investigators and sites for enrolling and treating trial participants. A per-subject payment that is not set at fair market value and tied to actual research services performed can independently trigger Stark or AKS liability, and claims tainted by an AKS violation are automatically treated as false claims under the FCA.
Who typically files qui tam cases involving clinical trial billing?
Research billing coordinators, hospital revenue-cycle or coding staff, and clinical research coordinators who reconcile charges against the coverage analysis and the clinical trial agreement in the normal course of their work are common relators in this context — a different profile from the lab managers and grants administrators who more often surface grant-side FCA concerns.
